Wellington Management Group
MCRB icon

Wellington Management Group’s Seres Therapeutics MCRB Stock Holding History

Wellington Management Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,966
Closed -$1.8M – 2247
2017
Q2 		$1.8M Sell
7,966
-1,311
-14% -$269K ﹤0.01% 1724
2017
Q1 		$2.09M Sell
9,277
-297
-3% -$60.3K ﹤0.01% 1727
2016
Q4 		$1.9M Buy
9,574
+570
+6% +$124K ﹤0.01% 1702
2016
Q3 		$2.21M Buy
9,004
+7,879
+700% +$2.76M ﹤0.01% 1623
2016
Q2 		$654K Buy
+1,125
New +$660K ﹤0.01% 1871

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group's MCRB Position: Q3 2017 in Review

Wellington Management Group sold out of Seres Therapeutics (MCRB) in Q3 2017, closing a stake of 7,966 shares — an estimated $1.8M sold.

Wellington Management Group first reported a position in MCRB in Q2 2016 and held it in 5 quarters. The position peaked at $2.21M in Q3 2016. 80 funds tracked by Wall St. Rank hold MCRB as of Q3 2017.

  • Wellington Management Group reported no remaining Seres Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Wellington Management Group sold 7,966 Seres Therapeutics shares in Q3 2017, an estimated $1.8M.
  • Wellington Management Group first reported a position in Seres Therapeutics in Q2 2016 and held it in 5 quarters.
  • Wellington Management Group's Seres Therapeutics position peaked at $2.21M in Q3 2016.
  • 80 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2017.

Based on Wellington Management Group's 13F filing for Q3 2017, filed 13 Nov 2017.